Goldman Sachs Group Inc. increased its position in shares of Core Laboratories N.V. (NYSE:CLB) by 156.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 68,823 shares of the oil and gas company’s stock after buying an additional 41,955 shares during the period. Goldman Sachs Group Inc. owned 0.16% of Core Laboratories N.V. worth $7,951,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Gulf International Bank UK Ltd increased its position in shares of Core Laboratories N.V. by 3.1% in the first quarter. Gulf International Bank UK Ltd now owns 13,449 shares of the oil and gas company’s stock worth $1,553,000 after buying an additional 400 shares in the last quarter. BTIM Corp. increased its position in shares of Core Laboratories N.V. by 6.3% in the first quarter. BTIM Corp. now owns 77,224 shares of the oil and gas company’s stock worth $8,921,000 after buying an additional 4,544 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Core Laboratories N.V. by 3.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 217,670 shares of the oil and gas company’s stock worth $26,128,000 after buying an additional 6,962 shares in the last quarter. Morgan Stanley increased its position in shares of Core Laboratories N.V. by 17.5% in the first quarter. Morgan Stanley now owns 167,465 shares of the oil and gas company’s stock worth $19,346,000 after buying an additional 24,929 shares in the last quarter. Finally, Comerica Securities Inc. increased its position in shares of Core Laboratories N.V. by 22.5% in the first quarter. Comerica Securities Inc. now owns 2,529 shares of the oil and gas company’s stock worth $292,000 after buying an additional 465 shares in the last quarter.
Shares of Core Laboratories N.V. (NYSE CLB) traded down 2.20% during mid-day trading on Tuesday, reaching $89.65. The company’s stock had a trading volume of 602,028 shares. The stock has a market capitalization of $3.96 billion, a price-to-earnings ratio of 55.00 and a beta of 1.60. Core Laboratories N.V. has a 52 week low of $89.64 and a 52 week high of $125.83. The company’s 50-day moving average is $101.27 and its 200-day moving average is $108.43.
Core Laboratories N.V. (NYSE:CLB) last issued its quarterly earnings data on Monday, July 24th. The oil and gas company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.51 by $0.01. The company had revenue of $163.90 million for the quarter, compared to analyst estimates of $168.23 million. Core Laboratories N.V. had a return on equity of 49.29% and a net margin of 11.80%. The business’s quarterly revenue was up 10.7% compared to the same quarter last year. During the same quarter last year, the company posted $0.35 earnings per share. Equities analysts predict that Core Laboratories N.V. will post $2.09 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Monday, August 14th. Shareholders of record on Monday, July 17th were issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 2.45%. The ex-dividend date was Thursday, July 13th. Core Laboratories N.V.’s payout ratio is 134.15%.
COPYRIGHT VIOLATION NOTICE: This report was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://stocknewstimes.com/2017/08/15/goldman-sachs-group-inc-raises-position-in-core-laboratories-n-v-clb-updated-updated-updated.html.
CLB has been the topic of a number of analyst reports. Loop Capital upgraded Core Laboratories N.V. from a “hold” rating to a “buy” rating and lifted their price target for the company from $125.00 to $130.00 in a report on Friday, April 21st. Zacks Investment Research downgraded Core Laboratories N.V. from a “buy” rating to a “hold” rating in a report on Friday, June 23rd. BidaskClub upgraded Core Laboratories N.V. from a “sell” rating to a “hold” rating in a research note on Wednesday, July 5th. Morgan Stanley dropped their target price on Core Laboratories N.V. from $130.00 to $125.00 and set an “overweight” rating on the stock in a research note on Monday, August 7th. Finally, ABN Amro upgraded Core Laboratories N.V. to a “hold” rating in a research note on Friday, April 21st. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $117.17.
About Core Laboratories N.V.
Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.
Receive News & Ratings for Core Laboratories N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories N.V. and related companies with MarketBeat.com's FREE daily email newsletter.
